The $10 million molecule: Juno Therapeutics’ acquisition of RedoxTherapies could improve cancer treatment Seattle-based Juno Therapeutics has acquired RedoxTherapies for $10 million, to secure exclusive rights to a molecule that may provide a new… Read More
